This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.
Adults age 18 or older
Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
No evidence of persistent or progressive malignancy at the time of enrollment
Agrees to be evaluated at the transplant center before a new line of treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
Inability to comply with study procedures
Uncontrolled psychiatric disorder
Anticipated survival < 6 months
Fred Hutchinson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator